INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate

Go back to INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate
INOVIO PHARMACEUTICALS, Inc. (NASDAQ: INO) Delayed: 1.16 +0.03 (2.65%)
Previous Close $1.13    52 Week High $11.69 
Open $1.12    52 Week Low $4.50 
Day High $1.19    P/E N/A 
Day Low $1.11    EPS $-0.28 
Volume 2,796,762